Feng Jiang

US Patent:

20120302629, Nov 29, 2012

Filed:

Jul 28, 2010

Appl. No.:

13/388610

Inventors:

Shaomeng Wang - Saline MI, US
Feng Jiang - Ann Arbor MI, US
Jianting Long - Guangzhou, CN
Longchuan Bai - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 31/11
C12Q 1/68
A61P 35/00
A61K 31/337
A61P 29/00
A61P 31/00
A61P 7/00
A61P 35/02
G01N 33/574
A61P 37/00

US Classification:

514449, 435 79, 435 611, 514700

Abstract:

The present invention provides a biomarker for selecting a patient for treatment with gossypol, wherein the biomarker comprises an elevated expression level of c-Myc, Mcl-1, or combination thereof, relative to the normal expression level of c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for targeting patients for treatment with gossypol, wherein the patient has a disease, condition, or disorder that overexpresses c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for treating or ameliorating a disease, condition, or disorder in a patient comprising determining the expression level of c-Myc, Mcl-1, or combination thereof in the patient and administering gossypol to the patient. In certain embodiments of the invention, the disease is cancer, and the cancer cells show elevated expression levels of c-Myc compared to non-cancerous cells. The invention also provides methods for overcoming Mcl-1-mediated chemoresistance comprising administering gossypol to a patient in need thereof.

US Patent:

20190000982, Jan 3, 2019

Filed:

Sep 4, 2018

Appl. No.:

16/120829

Inventors:

- Detroit MI, US
Qianqian Li - Troy MI, US
Michael Chopp - Southfield MI, US
Feng Jiang - Troy MI, US
Guojun Wu - Northville MI, US

Assignee:

Qurgen, Inc. - Troy MI

International Classification:

A61K 47/59
A61K 47/54
A61K 48/00
A61K 38/17
A61K 9/00

Abstract:

Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject.

US Patent:

20160263233, Sep 15, 2016

Filed:

Oct 27, 2014

Appl. No.:

15/031839

Inventors:

- Detroit MI, US
Qianqian Li - Troy MI, US
Michael Chopp - Southfield MI, US
Feng Jiang - Troy MI, US
Guojun Wu - Northville MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

A61K 47/48
A61K 38/17

Abstract:

Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject.